Question Title

* 1. First Name

Question Title

* 2. Last Name

Question Title

* 3. Email Address

Question Title

* 4. Specialty

Question Title

* 5. On a scale from 1 to 5, where 1 means "Not Important" and 5 means "Extremely important", how important is the financial reimbursement when treating your patients with denosumab (Prolia or XGEVA)? Please explain your reasoning.

Question Title

* 6. Please explain your reasoning to question 5.

Question Title

* 7. On a scale from 1 to 5, where 1 means "Not Comfortable at All" and 5 means "Extremely Comfortable", how comfortable are you switching a stable Prolia/Xgeva patient to a biosimilar?

Question Title

* 8. Please explain your reasoning to question 7.

Question Title

* 9. Assume you are in a situation where you have 5 denosumab options (the originator brand and 4 new biosimilars). Also assume that the clinical profile, commercial payer coverage and financials are all highly similar for all options. Also assume that 4 of the denosumabs have a permanent reimbursement code and 1 option, Product X, does not, and requires a Miscellaneous code for reimbursement. On a scale from 1 to 5, where 1 means "No Negative Impact" and 5 means "Extremely Negative Impact," to what extent would the use of a miscellaneous reimbursement code negatively impact your willingness to prescribe Product X?

Question Title

* 10. Please explain your reasoning to question 9.

Question Title

* 11. In the scenario above with 4 new denosumab biosimilars in the market, which of the factors listed will have the greatest impact on your biosimilar choice?

T